Antisense Oligonucleotides Market
Regional Analysis:-
North America is expected to be
the dominant region in the global Antisense
Oligonucleotides Market over the forecast period. This is owing to
increasing approvals of new antisense oligonucleotide drugs in the region. For
instance, in 2018, U.S. FDA approved Nusinersen, which is marketed as Spinraza
from Biogen Inc.—a multinational biotechnology company. Nusinersen is the first
drug approved for the treatment of Spinal muscular Atrophy (SMA). Moreover,
robust pipeline is expected to contribute significantly to North America
antisense oligonucleotides market growth. For instance, in 2017, Bio Path
Holding’s—an oncology focused biotechnology company— drug BP 1001 (liposomal
Grb2 antisense oligonucleotide) was in phase 2 clinical trials. BP 1001
(liposomal Grb2 antisense oligonucleotide) is used to treat chronic myelogenous
leukemia.
Key players in Europe are focusing
on strategic mergers and acquisitions in order to enhance their product
offerings in antisense oligonucleotides. This is further expected to aid in
growth of the Europe antisense oligonucleotides market size. For instance, in
2014, Astra Zeneca Plc.,—a multinational pharmaceutical and biopharmaceutical
company—merged with Ionis Pharmaceuticals, a pharmaceutical company. Astra
Zeneca Plc. has strategically merged with Ionis Pharmaceuticals to develop
delivery methods for antisense oligonucleotides, which would help in targeting
the desired tissue more effectively. The other objective of this merger was to
develop Ligand Conjugation Antisense (LICA) Technology. Furthermore, robust
pipeline of key players is also expected to aid in growth of the market to a
certain extent. For instance, in 2016, Ionis Pharmaceuticals, a pharmaceutical
company completed phase 2 clinical trial of its drug IONIS STAT 3Rx. IONIS STAT
3Rx is used in treatment of advanced cancers and lymphoma.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1879
Antisense oligonucleotides are
short, single stranded RNA or DNA molecules. Antisense oligonucleotides do not
modulate the activity of already formed proteins, however they act before
proteins are produced at the level of messenger RNA in the cell. Antisense
oligonucleotides is used in treatment of oncology, Central nervous system
therapeutics, inflammation therapeutics, diabetes, asthma, hair loss, etc.
Antisense oligonucleotides is also used in genomics. Some examples of antisense
nucleotides are fomivirsen to treat cytomegalovirus retinitis, mipomersen to
treat high cholesterol, etc.
Antisense Oligonucleotides Market
Drivers:-
One of the major factors driving
growth of the global antisense oligonucleotides market is increasing number of
launches pertaining to novel Antisense Oligonucleotides products by key players
in the market. For instance, in 2015, Exiqon A/S acquired by Qiagen launched
new LNA Antisense Oligonucleotide GapmeRs. LNA Antisense Oligonucleotide
GapmeRs is used for inactivation of RNA in functional analysis. Antisense LNA
is an alternative to existing siRNAs. LNA Antisense Oligonucleotide are
designed using advanced bioinformatics algorithm, which is combined with LNA
(locked nucleic acid).
Furthermore, mergers and
acquisitions by key players, in order to enhance their product offerings is
expected to be a major driver for global antisense oligonucleotides market
growth. For instance, in February 2018, Takeda Pharmaceuticals Company Ltd.—a
pharmaceutical company—merged with Wave Life Sciences Ltd., which is involved
in nuclei acid therapeutics. Takeda Pharmaceuticals has merged with Wave Life
Sciences Ltd. to develop antisense oligonucleotides for central nervous system
disorder, which includes Lou Gehrig’s disease, Frontotemporal dementia (FTD),
Spinocerebellar ataxia type 3 (SCA3), and huntington’s disease. Lou Gehrig’s
disease is also called as Amyotrophic lateral sclerosis (ALS). This acquisition
will also help Takeda in gaining market share.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/antisense-oligonucleotides-market-1879
Robust pipeline is also another
factor aiding in growth of the global market. For instance, in 2016 Ionis
Pharmaceuticals completed phase 2 clinical trials of its ISIS CRP Rx. ISIS
329993 is an antisense oligonucleotide, which targets CRP (C reactive protein)
in patients with paroxysmal atrial fibrillation. In 2015, Achieve Life Sciences
completed Phase 2 clinical trials of its OGX 427. OGX 427 is used to treat
castration resistant prostate cancer.
Antisense Oligonucleotides Market
Key Players:-
Key players in global antisense
oligonucleotides market include Ionis Pharmaceuticals Inc., Sarepta
Therapeutics Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Antisense
Therapeutics Ltd., Isarna Therapeutics GmbH, Arrowhead Pharmaceuticals Inc.,
Atlantic pharmaceuticals Inc., Enzon Pharmaceuticals Inc., Bio-Path Holdings
Inc., Glaxo smith Kline Plc., Gene Signal International SA., Geron Corporation,
Gradlis Inc., ICO Therapeutics Inc., Aptose Biosciences Inc., Marina Biotech
Inc., miRagen Therapeutics Inc., Synlogic Inc., OncoGenex Pharmaceuticals Inc.,
Pharmaxis Ltd., Rexahn Pharmaceuticals Inc., Regulus Therapeutics Inc., and Rxi
Pharmaceuticals Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1879
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment